Filing Date July 13, 2001  For be assigned  From Part Unit 1645  To be assigned  From Part Unit 1645  To The COMMISSIONER FOR PATENTS  Transmitted herewith is an Information Disclosure Statement; Form PTO-1449; 2 cited references and return postcal  Small entity status of this application under 37 CFR § 1.27 has been established by verified statement previous submitted.  A verified statement to establish small entity status under 37 CFR § 1.9 and 1.27 is enclosed.  Petition for amonth extension of time.  No additional fee is required.  The fee has been calculated as shown below:  Claims Remaining After Amendment  Minus  Filing Date From Part Extra  From PTO-1449; 2 cited references and return postcal From PTO-1449; 2 cited referenc	Server No.		TRANSMITTAL L	ETTER				Case	No. 10466/54	
Inventor(s) Ashkenazi et al.  Title of Inventor(s) Ashkenazi et al.  Title of Inventor SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC ACIDS ENCODING THE SAME  TO THE COMMISSIONER FOR PATENTS  Transmitted herewith is an Information Disclosure Statement; Form PTO-1449; 2 cited references and return postcar  Small entity status of this application under 37 CFR § 1.27 has been established by verified statement previous by being the statement of time.  A verified statement to establish small entity status under 37 CFR §§ 1.9 and 1.27 is enclosed.  Petition for amonth extension of time.  No additional fee is required.  The fee has been calculated as shown below:  Claims	-00/00/ 838		•					Group		
Title of Invention SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC ACIDS ENCODING THE SAME  TO THE COMMISSIONER FOR PATENTS  Transmitted herewith is an Information Disclosure Statement; Form PTO-1449; 2 cited references and return postcar  Small entity status of this application under 37 CFR § 1.27 has been established by verified statement previous minuted.  A verified statement to establish small entity status under 37 CFR §§ 1.9 and 1.27 is enclosed.  Petition for amonth extension of time.  No additional fee is required.  The fee has been calculated as shown below:  Claims Remaining After Aft	Inventor(s)	Jul	y 13, 2001		To be as	signed		1645		
Transmitted herewith is an Information Disclosure Statement: Form PTO-1449; 2 cited references and return postcal  Small entity status of this application under 37 CFR § 1.27 has been established by verified statement previously and the statement of establish small entity status under 37 CFR §§ 1.9 and 1.27 is enclosed.  Petition for amonth extension of time.  No additional fee is required.  The fee has been calculated as shown below:  Claims Remaining After Amendment  Claims Remaining After Amendment  Minus  Total Minus  Minus  Minus  Total S  Total \$										
TO THE COMMISSIONER FOR PATENTS  Transmitted herewith is an Information Disclosure Statement; Form PTO-1449; 2 cited references and return postcar  Small entity status of this application under 37 CFR § 1.27 has been established by verified statement previously and the statement to establish small entity status under 37 CFR §§ 1.9 and 1.27 is enclosed.  Petition for amonth extension of time.  No additional fee is required.  The fee has been calculated as shown below:  Claims Remaining After Amendment  Highest No. Previously Paid For Extra  Rate  Add'I Fee  Rate  Rate  First Presentation of Multiple Dep. Claim  Total \$		NSMEMBRAN	NE POLYPEPTIDE	ES AND NUC	CLEIC AC	IDS ENCODI	IG THE S	AME		
Transmitted herewith is an Information Disclosure Statement; Form PTO-1449; 2 cited references and return postcal  Small entity status of this application under 37 CFR § 1.27 has been established by verified statement previously and the statement to establish small entity status under 37 CFR §§ 1.9 and 1.27 is enclosed.  Petition for amonth extension of time.  No additional fee is required.  The fee has been calculated as shown below:  Claims Remaining After Amendment  Remaining After Amendment  Minus  Total Minus  Minus  Total Minus  Minus  Total S  Total \$  Total \$			TO THE C	OMMISSION	VER FOR	PATENTS				
Small entity status of this application under 37 CFR § 1.27 has been established by verified statement previously Previously Paid For Extra  Small entity status of this application under 37 CFR § 1.27 has been established by verified statement previously Present Extra  Small Entity  Claims Remaining After Amendment  Total Minus  Indep. Minus  First Presentation of Multiple Dep. Claim  Small entity status under 37 CFR § 1.9 and 1.27 is enclosed.  Small Entity  Small Entity  Other The Small Entity  Rate Add'l Fee  x \$9=	Transmitted	horowith is an				+				
Remaining After Amendment  Total Minus  Indep. Minus  First Presentation of Multiple Dep. Claim  Highest No. Previously Present Extra  Present Extra  Rate  Add'I Fee  Rate  Add'I Fee   x \$18=  x \$42=  +\$140=  Total \$  Total \$									and return pos	stcard
Remaining After Amendment  Total Minus  Indep. Minus  First Presentation of Multiple Dep. Claim  Highest No. Previously Present Extra  Present Extra  Rate  Add'I Fee  Rate  Add'I Fee   x \$18=  x \$42=  +\$140=  Total \$  Total \$	Small entity	status of this	application unde	er 37 CFR	§ 1.27 h	as been esta	olished by	y verifie	ed statement	previ
Remaining After Amendment  Total Minus  Indep. Minus  First Presentation of Multiple Dep. Claim  Highest No. Previously Present Extra  Present Extra  Rate  Add'I Fee  Rate  Add'I Fee   x \$18=  x \$42=  +\$140=  Total \$  Total \$									/	XX
Remaining After Amendment  Total Minus  Indep. Minus  First Presentation of Multiple Dep. Claim  Highest No. Previously Present Extra  Present Extra  Rate  Add'I Fee  Rate  Add'I Fee   x \$18=  x \$42=  +\$140=  Total \$  Total \$	A verified sta	itement to esta	iblish small entity	status under	37 CFR	§§ 1.9 and 1.2	7 is enclos	sed.	,	
Remaining After Amendment  Total Minus  Indep. Minus  First Presentation of Multiple Dep. Claim  Highest No. Previously Present Extra  Present Extra  Rate  Add'I Fee  Rate  Add'I Fee   x \$18=  x \$42=  +\$140=  Total \$  Total \$	Petition for a	month	extension of time.						TEO.	14A
Remaining After Amendment  Total Minus  Indep. Minus  First Presentation of Multiple Dep. Claim  Highest No. Previously Present Extra  Present Extra  Rate  Add'I Fee  Rate  Add'I Fee   x \$18=  x \$42=  +\$140=  Total \$  Total \$									~ U.Z.	•
Remaining After Amendment  Total Minus  Indep. Minus  First Presentation of Multiple Dep. Claim  Highest No. Previously Present Extra  Present Extra  Rate  Add'I Fee  Rate  Add'I Fee   x \$18=  x \$42=  +\$140=  Total \$  Total \$	No additiona	I fee is require	d.						-17 Cc	1.
Remaining After Amendment  Total Minus  Indep. Minus  First Presentation of Multiple Dep. Claim  Highest No. Previously Paid For Extra  Present Extra  Rate  Add'I Fee  Rate  Add'I Fee   x \$18=  x \$42=  +\$140=  Total \$  Total \$		•		_					CEN	VIER
Remaining After Amendment  Total Minus  Indep. Minus  First Presentation of Multiple Dep. Claim  Highest No. Previously Present Extra  Present Extra  Rate  Add'I Fee  Rate  Add'I Fee   x \$18=  x \$42=  +\$140=  Total \$  Total \$		•		r.						TEK
After Amendment         Paid For         Extra         Rate         Fee         Rate         Fee           Total         Minus         x \$9=         x \$18=           Indep.         Minus         x 42=         x \$84=           First Presentation of Multiple Dep. Claim         +\$140=         +\$280=           Total         \$         Total         \$		•		r:		Small	Entity		Other Small	Tha Entit
Amendment	The fee has Claims	•	d as shown below			Small		or	Other Small	Tha Entit
Name	The fee has  Claims Remaining	•	d as shown below  Highest No. Previously	Present			Add'l	or		Ad
First Presentation of Multiple Dep. Claim +\$140= +\$280= Total \$ Total \$	Claims Remaining After	•	d as shown below  Highest No. Previously	Present			Add'l	or		Ad
Total \$ Total \$	Claims Remaining After Amendment	been calculate	d as shown below  Highest No. Previously	Present		Rate	Add'l	or	Rate	Ad
	Claims Remaining After Amendment	been calculate	d as shown below  Highest No. Previously	Present		Rate x \$9=	Add'l	or	Rate x \$18=	Ad
· · · · · · · · · · · · · · · · · · ·	Claims Remaining After Amendment Total Indep.	Minus Minus	d as shown below  Highest No. Previously Paid For	Present		Rate x \$9= x 42=	Add'l	or	Rate x \$18≈ x \$84=	Thar Entit
	Claims Remaining After Amendment Total Indep.	Minus Minus	d as shown below  Highest No. Previously Paid For	Present		x \$9= x 42= +\$140=	Add'I Fee	or	x \$18= x \$84= + \$280=	Ad Fe

overpayment to Deposit Account No. 23-1925. A duplicate copy of this sheet is enclosed.  $\boxtimes$ 

I hereby petition under 37 CFR § 1.136(a) for any extension of time required to ensure that this paper is timely filed. Please charge any associated fees which have not otherwise been paid to Deposit Account No. 23-1925. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

Gregory M. Zinkl, 4 h.D. Registration No. 48,492 Agent for Applicant

**BRINKS HOFER GILSON & LIONE** P.O. BOX 10395 CHICAGO, ILLINOIS 60610 (312) 321-4200

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail, with sufficient postage, in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231, on

CERTIFICATE OF MAILING

Hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope, with sufficient postage, addressed to: Commissioner for Patents, Washington, D.C. 20231, on

Date of Deposit

Gregory M. Zinkl, Ph.D.

Name of Applicant, Assignee or
Registered Representative

Signature

Date of Signature

Our Case No.: 10466/54

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner: To be assigned

Group Art Unit No.: 1645

In re Application of:

Ashkenazi et al.

Serial No.: 09/904,838

Filing Date: July 13, 2001

For:

MAR 1 4 2002

SECRETED AND TRANSMEMBRANE

POLYPEPTIDES AND NUCLEIC

ACIDS ENCODING THE SAME

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents Washington, D.C. 20231

Dear Sir:

In compliance with the duty of disclosure under 37 C.F.R. § 1.56, it is respectfully requested that this Information Disclosure Statement be entered and the documents listed below and on the attached Form PTO-1449 be considered by the Examiner and

made of record. Copies of the listed documents required by 37 C.F.R. § 1.98(a)(2) are enclosed for the convenience of the Examiner.

The references now cited are the following:

## **OTHER ART**

- 1. Blast Results A1-A16, GenBank
- 2. Blast Results, B1-B9, Dayhoff

In accordance with 37 C.F.R. § 1.97(g),(h), this Information Disclosure Statement is not to be construed as a representation that a search has been made and is not to be construed to be an admission that the information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

This Information Disclosure Statement is being filed prior to the receipt of the first Official Action reflecting an examination on the merits and hence is believed to be timely filed in accordance with 37 C.F.R. § 1.97(b). No fees are believed to be due in connection with filing of this Information Disclosure Statement, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to these material, the Commissioner is hereby authorized to deduct said fees from Brinks Hofer Gilson & Lione Deposit Account No. 23-1925. A duplicate copy of this document is enclosed.

Applicant(s) respectfully request that the listed documents be made of record in the present case.

Respectfully submitted,

Gregory M. Zinkl, Ph.D. Registration No. 48,492 Agent for Applicant(s)

**BRINKS HOFER GILSON & LIONE** P.O. Box 10395 Chicago, IL 60610 (312) 321-4200